Beyond chemotherapy — EGFR, KRAS G12C, ROS1, DLL3 targeted therapy, immunotherapy, and CAR-T trials are rewriting lung cancer outcomes. Find your molecularly-matched pathway across 7 countries.
2026 molecular classification: EGFR, KRAS G12C, ROS1, ALK, DLL3 — each requires a distinct pathway and country strategy.
EGFR mutation-positive non-small cell lung cancer — Osimertinib + chemo = 47.5 months median OS
KRAS G12C mutation — Olumorasib + chemoimmunotherapy = 61% ORR, 90% DCR
ROS1 fusion-positive — Zidesamtinib = 89% ORR (no prior TKI), 44% ORR (prior TKI)
DLL3-positive extensive-stage SCLC — Tarlatamab (bispecific antibody) FDA-approved 2025
Non-squamous restricted therapies not applicable — immunotherapy mainstay
EGFR, PD-L1, MUC1, CEA, ROR1-targeted CAR-T in Phase 1/2 trials
Your molecular profile determines your pathway. Find the optimal country for each biomarker-driven strategy.
Osimertinib + chemotherapy (FLAURA2) is the new first-line standard with 47.5 months median overall survival.
The "undruggable" target is now druggable. Olumorasib + chemoimmunotherapy = 61% ORR, 90% DCR.
FDA-approved 2025. Tarlatamab is a bispecific antibody for extensive-stage SCLC after platinum-based chemotherapy.
CAR-T for solid tumors targeting EGFR, PD-L1, MUC1, CEA, ROR1. Phase 1/2 trials in China, India, Germany.
Each country has a distinct role based on drug access, trial availability, cost, and speed.
Complete molecular-to-country routing: subtype × biomarker × treatment × best country × budget.
| Subtype / Biomarker | Optimal Treatment | Best Country | Budget | Urgency |
|---|---|---|---|---|
| NSCLC EGFR+ | Osimertinib + Chemo (FLAURA2) | 🇩🇪 Germany / 🇰🇷 Korea | $20K-$60K | High |
| NSCLC KRAS G12C+ | Olumorasib + Chemoimmunotherapy | 🇮🇳 India / 🇨🇳 China | $10K-$30K | High |
| NSCLC ROS1+ | Zidesamtinib | 🇩🇪 Germany / 🇰🇷 Korea | $20K-$60K | High |
| Squamous NSCLC | Immunotherapy + Chemo | 🇮🇳 India / 🇨🇳 China | $5K-$20K | High |
| SCLC Limited-Stage | Chemoimmunotherapy | 🇰🇷 Korea / 🇩🇪 Germany | $5K-$20K | High |
| SCLC DLL3+ Extensive | Tarlatamab (Bispecific Ab) | 🇨🇳 China / 🇮🇳 India | $10K-$30K | Critical |
| NSCLC (Trial) | CAR-T (EGFR/PD-L1/MUC1) | 🇨🇳 China / 🇩🇪 Germany | $40K-$80K | Medium |
| All Subtypes | Second Opinion | 🌍 All Countries | FREE | 48h |
How biomarker-driven treatment selection and country routing changed outcomes.
Progression on first-line Osimertinib. Referred to Charité Berlin for FLAURA2 protocol (Osimertinib + chemotherapy).
Newly diagnosed KRAS G12C+ NSCLC. Referred to Tata Memorial, India for Olumorasib + chemoimmunotherapy.
Extensive-stage SCLC, progression after platinum-based chemotherapy. DLL3 positive. Referred to CARsgen, China for Tarlatamab.
Essential tools for biomarker-driven lung cancer treatment decisions.
Required biomarkers for lung cancer treatment routing.
How fast can you access lung cancer treatment?
Everything needed for a lung cancer case review.
Key questions for your lung cancer second opinion.
Disclaimer: This is a decision-support tool, not medical advice. All treatment decisions are made by licensed physicians at partner institutions. Read our full Legal Framework →
Common questions about molecular testing, targeted therapy, and CAR-T access.
Yes. Immune checkpoint inhibitors (PD-1, PD-L1, TIGIT) improve survival in both NSCLC and SCLC. For non-squamous NSCLC, chemoimmunotherapy is first-line standard. For SCLC, chemoimmunotherapy + tarlatamab (FDA-approved 2025) significantly extends survival in extensive-stage disease.
Yes, but in clinical trials only. CAR-T targets for lung cancer include EGFR, PD-L1, MUC1, CEA, ROR1, and DLL3. Available in China, India, and Germany. ORR: 20-30% for NSCLC, 25-35% for SCLC. Costs range from $40,000-$80,000 in trials.
Tarlatamab is a bispecific antibody targeting DLL3, FDA-approved in 2025 for DLL3+ extensive-stage SCLC. It is available in China, India, and Korea. It significantly improves survival compared to standard chemotherapy in pretreated patients.
Germany, Korea, and Singapore offer premium access to Osimertinib + chemotherapy (FLAURA2 protocol) with median overall survival of 47.5 months. Costs range from $20,000-$60,000 for international patients. China and India offer cost-effective alternatives.
China, India, and Korea lead in KRAS G12C targeted therapy. Olumorasib + chemoimmunotherapy achieves 61% response rate and 90% disease control rate. India offers the lowest cost ($10,000-$30,000), 75% cheaper than US prices.
Essential: NGS panel (EGFR, KRAS, ROS1, ALK, BRAF, MET, RET, NTRK), PD-L1 IHC (22C3 or SP263), and for SCLC: DLL3 IHC. Liquid biopsy (ctDNA) is recommended for acquired resistance monitoring. Chinese labs offer rapid NGS in 7-10 days.
Submit your case for a free, no-obligation molecular assessment. Our thoracic oncology team will match your biomarker profile with the optimal destination and pathway within 48 hours.
Submit Your Case NowFree • Confidential • 48-Hour Response • No Obligation